Skip to main content
    K

    Kiora Pharmaceuticals Inc (KPRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.98
    -0.25 (-20.16%)

    Market Cap: $5.44M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Kiora Pharmaceuticals Inc (KPRX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Kiora Pharmaceuticals are Reviva Pharmaceuticals Holdings (RVPH), Theriva Biologics (TOVX) and PharmaCyte Biotech (PMCB). By market cap, Kiora Pharmaceuticals ranks 4th of the 13 companies on this page; Theriva Biologics (TOVX) is the largest at $6.61M.

    Peer Comparison

    KPRX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Kiora Pharmaceuticals (KPRX)$5.44MN/A6.2x0.0%N/A0.0%0.00%
    Reviva Pharmaceuticals Holdings Inc. (RVPH)$4.63MN/AN/A0.0%-90.2%0.0%0.00%
    Theriva Biologics Inc. (TOVX)$6.61MN/A21.5x0.0%-52.3%0.0%0.00%
    PharmaCyte Biotech Inc (PMCB)$3.77MN/AN/A0.0%N/A0.0%0.00%
    Processa Pharmaceuticals Inc (PCSA)$5.20MN/AN/A0.0%N/A0.0%0.00%
    GRI Bio Inc. (GRI)$3.72MN/AN/A0.0%N/A0.0%0.00%
    Imunon Inc (IMNN)$4.08MN/AN/A0.0%-131.5%0.0%0.00%
    Cadrenal Therapeutics, Inc. Common Stock (CVKD)$5.39MN/AN/A0.0%N/A0.0%0.00%
    Skye Bioscience, Inc. Common Stock (SKYE)$4.83MN/AN/A0.0%-3685.3%0.0%0.00%
    CNS Pharmaceuticals Inc (CNSP)$4.22MN/AN/A0.0%N/A0.0%0.00%
    Cardio Diagnostics Holdings Inc (CDIO)$5.59MN/A348.9x0.0%N/A25.7%0.00%
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)$4.02MN/AN/A0.0%-247.2%0.0%0.00%
    FibroBiologics, Inc. Common Stock (FBLG)$6.57MN/AN/A0.0%N/A0.0%0.00%
    Peer median$4.73MN/A185.2x0.0%-131.5%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Kiora Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Reviva Pharmaceuticals Holdings Inc. (RVPH)
    Reviva Pharmaceuticals Holdings Inc. (RVPH) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for central nervous...
    RVPH competitors
    Theriva Biologics Inc. (TOVX)
    Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need.
    TOVX competitors
    PharmaCyte Biotech Inc (PMCB)
    PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United...
    PMCB competitors
    Processa Pharmaceuticals Inc (PCSA)
    Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients...
    PCSA competitors
    GRI Bio Inc. (GRI)
    GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology.
    GRI competitors
    Imunon Inc (IMNN)
    Imunon Inc. is a clinical-stage biotechnology company at the forefront of developing innovative immune-mediated therapies targeting cancer and infectious...
    IMNN competitors
    Cadrenal Therapeutics, Inc. Common Stock (CVKD)
    Cadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical firm dedicated to developing groundbreaking therapies for renal diseases and associated...
    CVKD competitors
    Skye Bioscience, Inc. Common Stock (SKYE)
    Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops...
    SKYE competitors
    CNS Pharmaceuticals Inc (CNSP)
    CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central...
    CNSP competitors
    Cardio Diagnostics Holdings Inc (CDIO)
    Cardio Diagnostics Holdings Inc (CDIO) is a pioneering biotechnology firm focused on enhancing cardiovascular health through innovative diagnostic solutions.
    CDIO competitors
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)
    Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California.
    LIMN competitors
    FibroBiologics, Inc. Common Stock (FBLG)
    FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology...
    FBLG competitors

    Frequently Asked Questions About KPRX

    Who are Kiora Pharmaceuticals' main competitors?

    The companies most similar to Kiora Pharmaceuticals include Reviva Pharmaceuticals Holdings (RVPH), Theriva Biologics (TOVX), PharmaCyte Biotech (PMCB), Processa Pharmaceuticals (PCSA) and GRI Bio (GRI), listed from the closest match.

    Who is Kiora Pharmaceuticals' biggest competitor?

    Theriva Biologics (TOVX) is the largest of the similar companies at $6.61M; Reviva Pharmaceuticals Holdings (RVPH) is the closest match by business profile, size, sector and industry.

    How does KPRX stock compare with its competitors?

    KPRX's P/S is 6.2x against a peer median of 185.2x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Kiora Pharmaceuticals' competitors pays a higher dividend?

    Kiora Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Kiora Pharmaceuticals bigger than its competitors?

    No. Kiora Pharmaceuticals is 4th by market cap among the 13 companies on this page; the largest is Theriva Biologics (TOVX) at $6.61M.